GSK and Sanofi join forces in unprecedented vaccine collaboration to fight COVID-19 (14/04/2020)
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine. Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021.
GSK's major contributions to the fight against Covid-19 in Belgium: a minimum of 6000 screening tests per day and a donation of ten tons of protective equipment (08/04/2020)
GSK brings its expertise by carrying out tests in its laboratories against the coronavirus, thus
participating in a significant increase of the number of analyzes in our country. GSK will be
able to carry 6.000 tests per day. On top of this commitment we added the donation of ten tons of protective equipment. Local actions that join other initiatives and research projects carried out internationally by the company to fight the pandemic.
GSK Vaccines announces transformation plan (05/05/2020, Wavre)
On a new two-year program in preparation of the separation of GSK into two new companies: New GSK, a biopharmaceutical company with a common research and development approach (R&D) related to immune system science, the use of genetics and new technologies; and a new leading Consumer Healthcare company on the other hand.
GSK meets Belgian universities: Regional scientific associations bring together researchers from industry and universities (04/04/2019, Wavre)
On the scientific event "GSK meets Belgian Universities”, with the purpose of facilitating the exchange of ideas and deepening the dialogue on common vaccine research challenges.
Minister Bellot discovers mobility opportunities at GSK in Wavre (20/09/2018, Wavre)
About the mobility solutions that GSK, the largest private employer in Wallonia, offers its employees.